IAG CEO and Scientific Team to Present 5 Abstracts at EULAR in Amsterdam 2018

IAG CEO and Scientific Team to Present 5 Abstracts at EULAR in Amsterdam 2018

IAG’s scientific team will present our 5 abstracts and 1 publication in inflammatory arthritis, osteoarthritis, degenerative and genetic muscle diseases, scleroderma, rare musculoskeletal diseases at European League Against Rheumatism (#EULAR2018), 13-16 June 2018, Amsterdam, Netherlands

The works selected for publication are based on the results of innovative clinical research studies, which involve state-of-the-art and cutting-edge advanced imaging techniques, quantitative methodologies for assessment of treatment efficacy, including some that are based on machine learning and AI concepts. We warmly thank our collaborators, scientific advisors and biotechnology and pharmaceutical partners for their contributions and delighted to share the details of the abstracts below.

CHANGE IN MUSCLE VOLUME AND MUSCLE FAT FRACTION AS POTENTIAL NON-INVASIVE BIOMARKERS OF DISEASE PROGRESSION: MACHINE LEARNING FRAMEWORK FOR QUANTITATIVE ANALYSIS OF MRI DATA

In this study, we present a novel machine learning approach to segmentation of thigh muscles from MRI and the subsequent calculation of fat fraction from DIXON images to assess the quality of the muscle and its perfusion. We confirmed correlation between the manual and automated approaches to be 0.9396. Details of the method and discussion on measuring the treatment efficacy through the imaging biomarkers will be presented at EULAR,  Poster session II – 15.06.2018 from 11:45 to 13:30 – Poster area ‘Diagnostics and imaging procedures

 

DIGITAL ARTERY VOLUME INDEX: THE FIRST OBJECTIVE, NON INVASIVE IMAGING DIAGNOSTIC OF MACROVASCULAR INVOLVEMENT IN SCLERODERMA (SSC)

This study presents the first objective, non-invasive imaging diagnostic of macrovascular involvement in Scleroderma and assess its sensitivity to change in SSc patients. Its potential utility as an early diagnostic of neointima proliferation in SSc will be presented in Poster session II – 15.06.2018 from 11:45 to 13:30 – Poster area ‘Diagnostics and imaging procedures

 

QUANTITATIVE MRI OF SINGLE VS. MULTIPLE JOINTS IN JUVENILE IDIOPATHIC ARTHRITIS AS PREDICTIVE MEASURE OF CLINICAL OUTCOMES

In this study, we return to inflammatory disease assessment in patients with juvenile rheumatoid arthritis and provide consistent validation of Dynamic Enhanced MRI scores (DEMRIQ) against clinical examination, showing that DEMRIQ-V and DEMRIQ-ME scores, which either followed clinical response (DEMRIQ-ME) or predicted clinical outcomes at 6 months (DEMRIQ-V) in most patients can support early clinical and research decisions. Poster session II – 15.06.2018 from 11:45 to 13:30 – Poster area ‘Diagnostics and imaging procedures’ 

  

COMBINING FRACTAL- AND ENTROPY-BASED BONE TEXTURE ANALYSIS FOR THE PREDICTION OF OSTEOARTHRITIS: DATA FROM THE MULTICENTER OSTEOARTHRITIS STUDY

The purpose of the present study was to investigate if combining fractal- and entropy-based bone texture analyses with joint space width (JSW) and joint space area (JSA) may improve prediction of OA Poster session II – 15.06.2018 from 11:45 to 13:30 – Poster area ‘Diagnostics and imaging procedures’

 

AUTOMATED SCORING OF KNEE OSTEOARTHRITIS (OA) ON ROUTINE RADIOGRAPHS INDENTIFIES DISEASE SEVERITY IN OA

Knee osteoarthritis (OA) causes pain and limited function of the knee, and is linked to cartilage loss, bone remodeling and inflammation. To assess how joint space (JS) measures are related to pain and other clinical parameters, and whether JS measures can stratify patients into mild and advanced OA using an automated scoring tool. Poster session II – 15.06.2018 from 11:45 to 13:30 – Poster area ‘Diagnostics and imaging procedures’

 

DYNAMIC CONTRAST ENHANCED (DCE)-MRI IN RELATION TO INFLAMMATORY MARKERS IN SERUM AND JOINT FLUID: INITIAL DATA AND VALIDATION IN FOUR MOST COMMON KNEE ARTHRITIC DISEASES

In this study, we linked quantitative imaging and blood biomarkers of inflammation in the four most common knee arthritic diseases, RF + Rheumatoid Arthritis, RF- Rheumatoid Arthritis, Psoriatic Arthritis and Osteoarthritis, showing how imaging may have specific utility in differentiating these conditions, especially when multi-biomarker assays lacked complete sensitivity and specificity. Publication Only

 

To continue the discussion or schedule a meeting, please email contact@ia-grp.com  

 

 About EULAR

The European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavors to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems. For more information click here

About IAG

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

 

News
Events